



SAFETY DATA SHEET

Revision date 16-Jun-2025

Version 4

Page 1 / 13

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Product Code(s) PZ03381
Trade Name: Ondansetron Injection
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product for the treatment of nausea and vomiting (antiemetic)

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: This substance is classified as not hazardous according to regulation (EC) 1272/2008 [CLP].

OSHA Classification

Hazards not otherwise classified (HNOC)
Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200
Not applicable

2.2. Label elements

Signal word Not classified

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 2 / 13
Version 4

Hazard statements

Not classified in accordance with international standards for workplace safety.

- 0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity.
- 0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.
- 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).
- 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas).
- 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor).

Unknown aquatic toxicity

Contains 0 % of components with unknown hazards to the aquatic environment.

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Chemical name	EU - REACH (1907/2006) - Article 59(1) - Candidate List of Substances of Very High Concern (SVHC) for Authorisation	EU - REACH (1907/2006) - Endocrine Disruptor Assessment List of Substances
Propylparaben	-	Endocrine disrupting properties

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Ondansetron hydrochloride dihydrate (CAS #: 103639-04-9)	0.2		Not Listed	Acute Tox. 3 (H301) Aquatic. Acute 1 (H400) Aquatic. Chronic 1 (H410)	Not classified	1	1
Citric acid monohydrate (CAS #: 5949-29-1)	0.01 - 0.05	-	Not Listed	Skin Irrit. 2 (H315) Eye Irrit. 2 (H319)	Not classified	No data available	No data available

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 3 / 13
Version 4

				STOT SE 3 (H335)			
NonHazardous							
Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified	Not classified	No data available	No data available
Methyl-p-hydroxyben zoate (CAS #: 99-76-3)	>1		202-785-7	Not classified	Not classified	No data available	No data available
Sodium Citrate (CAS #: 6132-04-3)	*		612-118-5	Not classified	Not classified	No data available	No data available
Propylparaben (CAS #: 94-13-3)	> 1		202-307-7	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration $\geq 0.1\%$ (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 4 / 13
Version 4

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO₂, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 5 / 13
Version 4

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions

Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)

Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Ondansetron hydrochloride dihydrate

Pfizer OEL TWA-8 Hr: 10 µg/m³

SODIUM CHLORIDE

Latvia

TWA: 5 mg/m³;

Russia

MAC: 5 mg/m³

Methyl-p-hydroxybenzoate

Russia

MAC: 4 mg/m³

Propylparaben

Russia

MAC: 10 mg/m³

SODIUM CHLORIDE

Pfizer Occupational Exposure
Band (OEB):

OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 6 / 13
Version 4

Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).
Thermal hazards	No information available.
Environmental exposure controls	No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance	Solution
Physical state	Liquid
Color	Colorless
Odor	No information available.
Odor threshold	No information available

Property	Values
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	3.3 - 4.0
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

Partition Coefficient: (Method, pH, Endpoint, Value)

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 7 / 13
Version 4

Ondansetron hydrochloride dihydrate

Measured (TAD 3.02) 5 Log D 0.23
Measured (TAD 3.02) 7 Log D 1.00
Measured (TAD 3.02) 9 Log D 1.26

9.2. Other information

Molecular formula

Mixture

Molecular weight

Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity

No information available.

10.2. Chemical stability

Stability

Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid

Fine particles (such as mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials

As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:

The information included in this section describes the potential hazards of the individual ingredients

Short term

Active ingredient may be harmful if swallowed. May cause eye irritation (based on components)

Long Term:

May cause effects on central nervous system through prolonged or repeated exposure.

Known Clinical Effects:

Adverse effects associated with therapeutic use include headache, flushing, and constipation. May cause irregular heartbeat (cardiac arrhythmia), hypersensitivity reactions.

Acute toxicity

Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation

Based on available data, the classification criteria are not met.

Skin corrosion/irritation

Based on available data, the classification criteria are not met.

Respiratory or skin sensitization

Based on available data, the classification criteria are not met.

STOT - single exposure

Based on available data, the classification criteria are not met.

STOT - repeated exposure

Based on available data, the classification criteria are not met.

Reproductive toxicity

Based on available data, the classification criteria are not met.

Germ cell mutagenicity

Based on available data, the classification criteria are not met.

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 8 / 13
Version 4

Carcinogenicity Based on available data, the classification criteria are not met.
Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

Ondansetron hydrochloride dihydrate

Rat Oral LD50 95 mg/kg

Rat Para-periosteal LD50 20201 ug/kg

Dog Oral LD50 > 45 mg/kg

Methyl-p-hydroxybenzoate

Mouse Oral LD50 > 8 g/kg

Rat Oral LD 50 2100 mg/kg

Propylparaben

Mouse Oral LD 50 6332 mg/kg

Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
SODIUM CHLORIDE	= 3550 mg/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

0 % of the mixture consists of ingredient(s) of unknown acute toxicity.

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity.

0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas).

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor).

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

Methyl-p-hydroxybenzoate

Skin irritation Rabbit Non-irritating

Eye irritation Rabbit Slight

Skin Sensitization Guinea Pig Negative

Citric acid monohydrate

Eye Irritation Rabbit Moderate

Skin Irritation Rabbit Moderate

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ondansetron hydrochloride dihydrate

7 Week(s) Rat Oral 160 mg/kg/day Maximally Tolerated Dose

18 Month(s) Rat No route specified 1 mg/kg/day NOAEL Central Nervous System, Liver

12 Month(s) Dog No route specified 12 mg/kg/day NOAEL Central Nervous System, Liver

Methyl-p-hydroxybenzoate

28 Day(s) Rat Oral 250 mg/kg/day NOAEL Gastrointestinal System, Spleen, Thymus

Propylparaben

3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 9 / 13
Version 4

4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ondansetron hydrochloride dihydrate

Reproductive & Fertility Rat Oral 15 mg/kg/day NOAEL Negative

Fertility and Embryonic Development Rat Intravenous 4 mg/kg/day NOAEL No effects at maximum dose

Fertility and Embryonic Development Rabbit Intravenous 4 mg/kg/day NOAEL No effects at maximum dose

Methyl-p-hydroxybenzoate

Embryo / Fetal Development Rabbit Oral 300 mg/kg/day NOEL Maternal toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ondansetron hydrochloride dihydrate

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

In Vivo Chromosome Aberration Bone marrow Mouse Negative

Methyl-p-hydroxybenzoate

In Vivo Dominant Lethal Assay Rat Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ondansetron hydrochloride dihydrate

2 Year(s) Rat Oral 10 mg/kg/day NOAEL Not carcinogenic

2 Year(s) Mouse Oral 30 mg/kg/day NOAEL Not carcinogenic

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided. See aquatic toxicity data for individual components below.

Unknown aquatic toxicity Contains 0 % of components with unknown hazards to the aquatic environment.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ondansetron hydrochloride dihydrate

Selenastrum capricornutum (Green Alga) OECD 201 IC50 96 hours 3.1 mg/L

Selenastrum capricornutum (Green Alga) OECD 201 NOEC 96 hours 0.62 mg/L

Oncorhynchus mykiss (Rainbow Trout) OECD 203 LC50 96 hours 6.5 mg/L

Daphnia magna (Water Flea) OECD 202 EC50 48 Hours 28 mg/L

Methyl-p-hydroxybenzoate

Oryzias latipes (Japanese Rice Fish) OECD LC50 96 hours 59.5 mg/L

Daphnia magna (Water Flea) ISO EC50 48 hours 11.2 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Ondansetron hydrochloride dihydrate

Activated sludge OECD 209 EC50 > 1000 mg/L

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 10 / 13
Version 4

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

Ondansetron hydrochloride dihydrate

Ceriodaphnia dubia (Daphnids) USEPA 1002 7 Day(s) NOEC 0.32 mg/L Reproduction

12.2. Persistence and degradability

Persistence and degradability

Degradation:

Ondansetron hydrochloride dihydrate

OECD 302 Activated sludge Inherent 19 % in 28 Day(s)

Methyl-p-hydroxybenzoate

OECD Activated sludge Ultimate (CO2 Evolution) 89 % After 28 Day(s) Ready

12.3. Bioaccumulative potential

Bioaccumulation

Partition Coefficient: (Method, pH, Endpoint, Value)

Ondansetron hydrochloride dihydrate

Measured (TAD 3.02) 5 Log D 0.23

Measured (TAD 3.02) 7 Log D 1.00

Measured (TAD 3.02) 9 Log D 1.26

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	Not PBT/vPvB PBT assessment does not apply
Ondansetron hydrochloride dihydrate	Not PBT/vPvB
Methyl-p-hydroxybenzoate	Not PBT/vPvB
Citric acid monohydrate	Not PBT/vPvB
Sodium Citrate	Not PBT/vPvB PBT assessment does not apply
Propylparaben	Not PBT/vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 11 / 13
Version 4

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present

Ondansetron hydrochloride dihydrate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed

Methyl-p-hydroxybenzoate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	202-785-7
AICS	Present

Citric acid monohydrate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present

Sodium Citrate

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 12 / 13
Version 4

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5
Propylparaben	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	202-307-7
AICS	Present

National regulations

France

Occupational Illnesses (R-463-3, France)

Chemical name	French RG number
SODIUM CHLORIDE 7647-14-5	RG 78

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905

Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable

Storage of Hazardous Material Not applicable

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable

Major Accidents Ordinance SR 814.012 Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

EU - Plant Protection Products (1107/2009/EC)

Chemical name	EU - Plant Protection Products (1107/2009/EC)
SODIUM CHLORIDE 7647-14-5	Plant protection agent

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
SODIUM CHLORIDE 7647-14-5	Product-type 1: Human hygiene

SAFETY DATA SHEET

Product Name Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 13 / 13
Version 4

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H301 - Toxic if swallowed. H400 - Very toxic to aquatic life. H410 - Very toxic to aquatic life with long lasting effects. H315 - Causes skin irritation. H319 - Causes serious eye irritation. H335 - May cause respiratory irritation.

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

Reason for revision Updated Section 16 - Other Information.

Revision date 16-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.